Clinical Features, Prognosis, and Long-Term Response to Ranibizumab of Macular CNVs in Pattern Dystrophies Spectrum: A Pilot Study

Table 2

Longitudinal analysis.

	PD		AMD
	Variation	value	Variation	value
LogMAR, mean ± SD	0.31 ± 0.6	0.009	0.13 ± 0.65	0.4
CRT, µm, mean ± SD	−47.75 ± 123.07	0.046	−56.94 ± 204.28	0.25
SRF (%)	−61.6	0.004	−53.3	0.011
IRF (%)	22.1	0.52	−22.1	0.65
SHRM (%)	−30	0.034	−12.5	0.74
HRF (%)	−14.3	0.1	−50.0	0.011
HCD (%)	10.3	0.08	5.6	0.32
cCT, µm, mean ± SD	−27.48 ± 47.26	0.004	−18.61 ± 27.88	0.012
slCT, µm, mean ± SD	−27.93 ± 55.27	0.011	−5.0 ± 24.39	0.4
EZd (%)	13.79	0.21	16.63	0.08

PD, pattern dystrophies; AMD, age-related macular degeneration; LogMAR, visual acuity; CRT, central retinal thickness; SRF, subretinal fluid; IRF, intraretinal fluid; SHRM, subretinal hyperreflective material; HRF, hyperreflective foci; HCD, hyperreflective crystalline deposits; cCT, central choroidal thickness; slCT, sublesional choroidal thickness; EZd, ellipsoid zone disruption; SD, standard deviation; µm, micrometer. The chi-square test is for quantitative data, and the unpaired-t test is for qualitative data.